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Abstract
Introduction: In October 2015, the Food and Drug Administration (FDA) instituted an update to the
mandatory Risk Evaluation and Mitigation Strategy (REMS) program for clozapine to improve safety
monitoring of hematologic events. However, the impact of the clozapine REMS program on reporting of
hematologic adverse events has not been quantified.
Methods: We assessed adverse event reports for agranulocytosis, granulocytopenia, leukopenia, and
neutropenia from the FDA Adverse Event Reporting System (FAERS) for a 1-year time period before
(October 2014 to September 2015, pre-REMS) and after (October 2015 to September 2016, post-REMS) the
implementation of the clozapine REMS program. The AERSMine platform was used to capture historical
effect estimates (October 2004 to September 2014). Reporting odds ratios (ROR), proportional reporting
ratios (PRR), and corresponding Taylor series 95% confidence intervals (CIs) were calculated for hematologic
events with clozapine compared with all other medications using OpenEpi.
Results: Reporting rates for agranulocytosis, granulocytopenia, leukopenia, and neutropenia with clozapine
all increased from the pre-REMS to post-REMS time frames, ranging from a 2-fold increase with leukopenia
to a 40-fold increase with neutropenia; the composite measure of all hematologic reports had a 12-fold
increase. During the post-REMS time frame, the ROR increased by 1691% (111.4, 95% CI 100.6-123.4)
compared with the pre-REMS time frame (7.1, 95% CI 5.2-9.6), and the PRR increased by 1280% (83.1, 95%
CI 76.8-90.0 vs 6.9, 95% CI 5.1-9.4) for the composite outcome.
Discussion: We observed significant increases in reports of hematologic adverse events with clozapine after
the introduction of the clozapine REMS program. Future research should explore the impact of the less
stringent exclusionary and discontinuation criteria on utilization (eg, expanded access) and clinical outcomes
(eg, treatment effectiveness and adverse events).
Keywords: clozapine, neutropenia, pharmacovigilance, drug safety, agranulocytosis, granulocytopenia,
leukopenia, Risk Evaluation and Mitigation Strategy Program
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Introduction

The mechanism of action that causes these hematologic
changes is unknown and has not been shown to be dose
dependent.1 Risk of these reactions is greatest during the
first 18 weeks of therapy with subsequent decreases in risk
thereafter.1 With the body’s inability to properly protect
against pathogens, this can result in increased risk of
infections.10 Further, as the duration of these hematologic
reactions increases, the risk of infection increases, and
therefore, clinically managing these decreased WBC
counts becomes more difficult.10 In the event of
hematologic abnormalities necessitating clozapine discontinuation, it has been reported that discontinuation may
be associated with worsening psychiatric symptoms,
reduced quality of life, and increased risk of suicide.11-13
In October 2015, the mandatory FDA Risk Evaluation and
Mitigation Strategy (REMS) program for clozapine was
modified to improve safety monitoring in patients treated
with clozapine. A REMS program is a risk management
program that mandates safety monitoring activities that
may prevent occurrence of the event, reduce severity, or
identify the adverse event sooner.14 The clozapine REMS
program replaced the 6 existing prescribing registries that
were maintained by individual manufacturers of clozapine.15 The modified REMS program is shared by
prescribers, pharmacies, and patients in 1 centralized
program. Both prescribers and pharmacies must be
certified in the program in order to prescribe and dispense
clozapine, respectively. A requirement of the clozapine
REMS program is the monitoring of ANC before each

Methods
We reviewed reports submitted to the FDA’s Adverse
Event Reporting System (FAERS) for a 1-year time period
before (October 2014 through September 2015, preREMS) and after (October 2015 through September
2016, post-REMS) the implementation of the clozapine
REMS program.16 We only included initial reports and
excluded reports missing all 3 of the following: event date,
sex, and age. The AERSMine platform was also analyzed
for the time period of October 2004 through September
2014 to capture historical effect estimates.17 We identified
reactions from adverse event reports using the MedRA
terms (medical dictionary for regulatory activities) agranulocytosis, granulocytopenia, leukopenia, neutropenia, and
neutropenic, and subsequent listings of adverse events
were reviewed for inclusion. Reports were assessed for
mention of either the brand names Clozaril, Fazaclo,
Leponex, and Versacloz or the generic drug name
clozapine. The reporting odds ratio (ROR), proportional
reporting ratio (PRR),18 and corresponding Taylor series
95% confidence intervals (CIs) were calculated using
OpenEpi19 for all 3 time frames comparing clozapine
hematologic reports with all other medications. Although
the FDA label broadly refers to these hematologic
reactions as neutropenia, we assessed agranulocytosis,
granulocytopenia, leukopenia, and neutropenia individually and also as a composite reaction.

Results
During the 1-year pre-REMS time frame, there were
765 185 total adverse event reports, and clozapine was
listed in 0.27% of these reports (n ¼ 2048; Table 2). In the
1-year post-REMS time frame, there were 881 184 total
adverse event reports with clozapine comprising 0.26% of
reports (n ¼ 2248). In the 11-year historical time frame
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Clozapine is an atypical antipsychotic medication first
approved in the United States in 1989. US Food and Drug
Administration (FDA) approved indications include treatment-resistant schizophrenia as well as suicidal behavior
in schizophrenia or schizoaffective disorder.1 Clozapine
has been shown to be 1 of the most effective treatment
options available for these 2 indications and is recommended as a potential first-line treatment option.2-4 Even
with clozapine’s documented effectiveness, it is considered to be underutilized, in part due to its severe side
effect profile.5 Clozapine has several black box warnings
regarding potential severe adverse drug reactions (ADRs),
including hematologic abnormalities.1 Although the label
specifically mentions neutropenia, there are 3 additional
hematologic abnormalities that are clinically similar but
have different defining parameters: agranulocytosis,
granulocytopenia, and leukopenia. Agranulocytosis is
defined as having an absolute neutrophil count (ANC)
below 500/lL.6 Granulocytopenia is defined as an ANC
between 500/lL and 1000/lL.7 Leukopenia is defined as
have a total white blood cell (WBC) count of less than
4000/lL.8 Neutropenia is defined as having an ANC below
1500/lL.9

prescription of clozapine can be dispensed.15 Some
additional components of this modified REMS program
include lowering the discontinuation threshold from an
ANC of less than 1500/lL to an ANC of less than 1000/lL
as well as allowing patients with benign ethnic neutropenia to be treated with clozapine (Table 1). The purpose of
initiating this new mandatory REMS program was ‘‘to
address continuing safety concerns and current knowledge about a serious blood condition called severe
neutropenia.’’15(p1) The impact of the REMS program on
addressing safety concerns with neutropenia is not well
defined. Therefore, the objective of our study was to
assess adverse event reporting rates of hematologic
events with clozapine before and after the implementation of the clozapine REMS program.

TABLE 1: Changes in the clozapine Risk Evaluation and Mitigation Strategy (REMS) program (October 2015)15
Pre-REMSa

Post-REMSa
No WBC count monitoring
Dose discontinuation recommended if ANC ,1000
The NNRMF was discontinued

Patients with BEN

Dose discontinuation recommended if WBC ,3000
Dose discontinuation recommended if ANC ,1500
Patients were listed in the NNRMF if they had
WBC ,2000 or ANC ,1000
Patients are not able to receive treatment

Rechallenge

Not allowed if WBC ,2000 or ANC ,1000

WBC count monitoring
ANC
NNRMF

Patients are able to receive treatment; dose
discontinuation recommended if ANC ,500
Is not recommended, but prescribers are allowed to
if they determine the benefit outweighs the risk

ANC ¼ absolute neutrophil count; BEN ¼ benign ethnic neutropenia; NNRMF ¼ national non-rechallenge master file; WBC ¼ white blood cell.
a

Units in cells/lL.

During the pre-REMS time frame, the ROR for agranulocytosis with clozapine was 29.3 (95% CI 19.1-44.8) and a
PRR of 29.0 (95% CI 19.0-44.2), which were similar to the
historical time frame (ROR 23.2, 95% CI 21.6-24.8; PRR
22.7, 95% CI 21.2-24.3; Table 3). During the post-REMS
time frame, the ROR increased by 397% (116.2, 95% CI
93.0-145.2) compared with the pre-REMS time frame, and
the PRR increased by 382% (110.9, 95% CI 89.5-137.5).
For granulocytopenia, the pre-REMS ROR was 168.4 (95%
CI 76.6-370.3), and the PRR was 167.7 (95% CI 76.5-367.8),
which were 1.7 times lower than the historical reporting
rates (ROR 292.7, 95% CI 272.2-314.7; PRR 277.4, 95% CI
258.3-297.9). During the post-REMS time frame, there was
more than a 13.4-fold increase in the ROR (2261.3, 95% CI
1546.0-3306.0) and a 12.5-fold increase in the PRR
(2089.3, 95% CI 1436.0-3041.0) compared with the preREMS reporting rates.

The pre-REMS reporting rates for leukopenia with
clozapine were almost 3 times lower with an ROR of 4.5
(95% CI 1.7-12.0) and a PRR of 4.5 (95% CI 1.7-12.0) than
the historical reporting rates (ROR 13.6, 95% CI 13.0-14.3;
PRR 13.1, 95% CI 12.5-13.8). The post-REMS reporting
rates were more than double those of the pre-REMS time
frame but slightly lower than the historical reporting rates
with an ROR of 10.3 (95% CI 5.1-20.9) and a PRR of 10.3
(95% CI 5.1-20.7).
The pre-REMS and historical reporting rates for neutropenia with clozapine were lower than with the other
reactions (pre-REMS ROR 1.4, 95% CI 0.6-3.1; PRR 1.4,
95% CI 0.6-3.1; historical ROR 10.8, 95% CI 10.5-11.2; PRR
9.8, 95% CI 9.5-10.1). During the post-REMS time frame,
there was a 41-fold increase in reporting rates compared
with the pre-REMS time frames with an ROR of 65.6 (95%
CI 57.6-74.8) and a PRR of 57.2 (95% CI 51.0-64.2).
The composite measure of all hematologic reactions with
clozapine produced a historical estimate with an ROR of

TABLE 2: Clozapine adverse reactions in the Food and Drug Administration Adverse Event Reporting System

Total reactions
Total clozapine reactions
Total agranulocytosis reactions
Clozapine agranuloytosis reactions
Total granulocytopenia reactions
Clozapine granulocytopenia reactions
Total leukopenia reactions
Clozapine leukopenia reactions
Total neutropenia reactions
Clozapine neutropenia reactions
Total hematologic reactions
Clozapine hematologic reactions

Historical: Oct 2004
to Sept 2014

Pre-REMS: Oct 2014
to Sept 2015

Post-REMS: Oct 2015
to Sept 2016

5 828 458
44 168
6468
955
3408
2315
19 641
1787
68 722
4772
98 239
9829

765 185
2048
319
23
29
9
337
4
1615
6
2300
42

881 184
2248
466
103
203
171
312
8
2304
294
3285
576

REMS ¼ Risk Evaluation and Mitigation Strategy.
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prior to REMS, there were 5 828 458 total adverse event
reports, and 0.76% included clozapine (n ¼ 44 164).

TABLE 3: Risk estimates with corresponding 95% confidence intervals for hematologic adverse reactions with clozapine in
the Food and Drug Administration Adverse Event Reporting System
Historical: Oct 2004 to Sept 2014
ROR

PRR

Pre-REMS: Oct 2014 to Sept 2015
ROR

PRR

Post-REMS: Oct 2015 to Sept 2016
ROR

PRR

Agranulocytosis
23.2 (21.6-24.8)
22.7 (21.2-24.3)
29.3 (19.1-44.8) 29.0 (19.0-44.2)
116.2 (93.0-145.2)
110.9 (89.5-137.5)
Granulocytopenia 292.7 (272.2-314.7) 277.4 (258.3-297.9) 168.4 (76.6-370.3) 167.7 (76.5-367.8) 2261.3 (1546.0-3306.0) 2089.3 (1436.0-3041.0)
Leukopenia
13.6 (13.0-14.3)
13.1 (12.5-13.8)
4.5 (1.7-12.0)
4.5 (1.7-12.0)
10.3 (5.1-20.9)
10.3 (5.1-20.7)
Neutropenia
10.8 (10.5-11.2)
9.8 (9.5-10.1)
1.4 (0.6-3.1)
1.4 (0.6-3.1)
65.6 (57.6-74.8)
57.2 (51.0-64.2)
Composite
18.4 (18.0-18.9)
14.6 (14.3-14.8)
7.1 (5.2-9.6(
6.9 (5.1-9.4)
111.4 (100.6-123.4)
83.1 (76.8-90.0)
PRR ¼ proportional reporting ratio; REMS ¼ Risk Evaluation and Mitigation Strategy; ROR ¼ reporting odds ratio.

Three of the adverse reactions assessed had statistically
significant increases in effect estimates of at least a 4-fold
increase and nonoverlapping confidence intervals from
the historical time frame to the post-REMS time frame
although leukopenia had a decrease. Neutropenia had the
largest increase from the pre-REMS to the post-REMS
time frame with a greater than 40-fold increase in the
measures of association (ROR: 65.6; PRR: 57.2 vs ROR:
1.4; PRR: 1.4). The composite measure of all hematologic
reactions had greater than a 5-fold increase in the postREMS study period compared with the historical period
and greater than a 12-fold increase compared with the 1year pre-REMS period.

Discussion
To our knowledge, ours is the first study to assess
hematologic adverse event reports with clozapine following the implementation of the clozapine REMS program.
Our study showed significant increases in reports of
hematologic adverse events with clozapine after the
introduction of the clozapine REMS program. Reporting
rates for agranulocytosis, granulocytopenia, leukopenia,
and neutropenia with clozapine all increased from the preREMS to post-REMS time frames, ranging from a 2-fold
increase with leukopenia to a 40-fold increase with
neutropenia, and the composite measure of all hematologic reports had a 12-fold increase.
Conversion to a centralized clozapine REMS program now
allows pharmacies and prescribers to monitor patients
within a single, centralized system, eliminating reporting
burden and potential confusion and discrepancies when
there were 6 separate registries. There are several possible
explanations for the significant increase in reporting rates

of these adverse reactions since implementation of the
revised REMS program, including changes in exclusionary
criteria, monitoring parameters, and renewed attention to
safety monitoring with clozapine. For example, under to
the clozapine REMS program, providers are instructed to
report clozapine-related adverse events directly to the
Clozapine REMS Program Contact Center. Providers are
also encouraged to submit an adverse event report to the
FDA MedWatch Reporting System. Therefore, submission
of adverse event reports to the Clozapine REMS Program
Contact Center may increase voluntary reporting to the
FDA MedWatch Reporting System.
The clozapine REMS program requires monitoring for
neutropenia only by ANC before each prescription
dispensing, whereas previously it was monitored by ANC
in conjunction with WBC count (Table 1).15 Although the
frequency of this monitoring has remained the same, the
clozapine REMS program amended the discontinuation
threshold for patients from an ANC of less than 1500/lL to
an ANC of less than 1000/lL. Another update is that
patients who have benign ethnic neutropenia are now
able to be treated with clozapine although they were not
eligible prior to the modified REMS program. Another
change is that prescribers are allowed to rechallenge
patients if they believe the benefits outweigh the risks,
whereas previously, patients with either a WBC count of
less than 2000/lL or ANC less than 1000/lL were placed
on the National Non-Rechallenge Master File list and were
not allowed to rechallenge.
Clozapine is an effective treatment option and may be 1 of
the last options available for patients who have failed
previous therapies. Under the clozapine REMS program,
less stringent parameters for exclusion, discontinuation,
and rechallenge (Table 1) may have expanded access to
clozapine. One study20 conducted in a single state
psychiatric hospital found that clozapine prescribing had
a nonsignificant increase in the 6 months following the
REMS implementation. As such, our findings of increased
hematologic adverse event reporting with clozapine after
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18.4 (95% CI 18.0-18.9) and a PRR of 14.6 (95% CI 14.314.8) and a pre-REMS ROR of 7.1 (95% CI 5.2-9.6) and a
PRR of 6.9 (95% CI 5.1-9.4). During the post-REMS time
frame, the ROR increased by 1569% (111.4, 95% CI 100.6123.4) compared with the pre-REMS time frame, and the
PRR increased by 1204% (83.1, 95% CI 76.8-90.0).

the introduction of the clozapine REMS program may be
due to increased utilization of clozapine.

The historical and pre-REMS reporting rates from our
study were similar to others in the literature. A
population-based case control study22 conducted in Hong
Kong reported a crude odds ratio of 36.0 (95% CI 4.6284.2) for agranulocytosis with clozapine from January
2004 through December 2013. Another case control
study,23 conducted in Berlin from 2000 through 2010,
reported an odds ratio of 49.7 (95% CI 6.0-999.0) for
agranulocytosis with clozapine after adjusting for age and
sex. As these case-control studies were small, the CIs were
wide. However, the effect estimated indicates a large,
statically significant increased risk of agranulocytosis with
clozapine as we observed in our study.
The FDA has made further modifications to the clozapine
REMS program. As part of this update, which took effect
February 28, 2019, prescribers are not required to be
certified in the REMS program in order to prescribe
clozapine in the inpatient setting as long as the patient is
already enrolled in the program.24 In addition, pharmacies
are no longer allowed to enroll patients in the clozapine
REMS program, and only the prescriber or the prescriber’s
designee may enroll patients.24 It is unclear how these
changes to the program have affected adverse event
reporting and is an area of further evaluation.
There were several limitations to our study in addition to
the notoriety effect listed previously. First and foremost,
neither incidence nor prevalence of either the exposure
(clozapine) or the outcome (hematologic events) can be
quantified from the FAERS database.25-27 In addition,
causality does not need to be established between the
medication and ADR in order for it to be reported and
documented in FAERS.27 Underreporting of known ADRs

The centralized clozapine REMS program enhances
tracking of patients and their laboratory values for all
health care providers involved in an effort to improve
patient outcomes. There was greater than a 2-fold
increase in risk estimates for agranulocytosis, granulocytopenia, leukopenia, and neutropenia with the composite
measure having a 12-fold increase after REMS introduction compared to the previous year’s reporting rates.
Although more hematologic events are being reported
since the modified clozapine REMS program was initiated,
it remains unclear how this REMS program may be
impacting clinical outcomes in patients. With new
requirements being added to the REMS program in
February 2019, future research should evaluate the effect
of the clozapine REMS program, including access and
utilization as well as positive clinical outcomes, such as
treatment effectiveness and early detection of safety
events, and negative clinical outcomes, such as increased
incidence of serious hematologic reactions and progression to more severe hematologic conditions.
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